The approval of the topical glycopyrronium tosylate (Qbrexza, Dermira) for primary axillary hyperhidrosis may soon be followed by other treatments for the condition, says David M. Pariser, M.D., FAAD, in a presentation made at the Fall Clinical Dermatology Conference taking place this week in Las Vegas.

“It’s really exciting that there is something new after a period of 12 years or so of drought in innovation,” said Dr. Pariser, of the Eastern Virginia Medical School in Norfolk, Va. “Not only is there something new, but there are several new things in the pipeline for patients.”
Read more at Dermatology Times >>